Navigation Links
Sunesis Pharmaceuticals to Present Data at the Annual Meeting of,the American Association for Cancer Research

SOUTH SAN FRANCISCO, Calif., April 13, 2007 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. today announced that the company will present data at the Annual Meeting of the American Association for Cancer Research (AACR) being held April 14-18, 2007 in Los Angeles, California.

Data being presented in a poster session will focus on non-clinical data on SNS-032, a highly selective and potent inhibitor of cyclin-dependent kinases (CDKs) 2, 7 and 9 that is currently in a Phase 1 clinical trial for B-cell malignancies. Abstract #1815: "SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives apoptosis in the multiple myeloma cell line RPMI-8226" will be presented on Monday, April 16, 2007 from 8:00 a.m. to 12:00 p.m. in poster section 7, board #1.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling. Sunesis is currently conducting Phase 2 clinical trials in lung and ovarian cancer and a Phase 1 clinical trial in acute myeloid leukemia for its lead compound, SNS-595. SNS-032, Sunesis' CDK inhibitor compound, is being evaluated in Phase 1 clinical trials in B-cell malignancies and in advanced solid tumors. The company's Aurora kinase inhibitor, SNS-314 is expected to begin Phase 1 clinical trials in the first half of 2007. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and other oncology kinases in collaboration with Biogen Idec.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of targeted cancer therapeutics. Sunes
'"/>




Page: 1 2

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
3. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
4. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
5. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings

Post Your Comments:
(Date:11/6/2009)...-- Cyberonics, Inc. (Nasdaq: CYBX ) today announc...for the second quarter ended October 23, 2009 of i... November 18, 2009 at 5:00 PM EST. The company wi...lts on Thursday, November 19, 2009 at 9:00 AM EST....onference Call Instructions ,, To listen to t...
(Date:11/6/2009)...-- Caraco Pharmaceutical Laboratories, Ltd. (NYSE ...phthalmic solution, 0.5% following a final approva...or Sun Pharma,s Abbreviated New Drug Application (...on the first day following patent expiration. This...nt to Acular® Ophthalmic Solution, 0.5%, from...
(Date:11/5/2009)...stCall/ -- Osteotech, Inc. (Nasdaq: OSTE ), a lea... regenerative healing, today reported financial re...09. ,, "During the third quarter of 2009, our f...products MagniFuse(TM) Bone Graft, FacetLinx(TM) ...afting," said Sam Owusu-Akyaw, President and Chief...
Breaking Medicine Technology:Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results 2Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution 2Osteotech Reports Third Quarter 2009 Financial Results 2Osteotech Reports Third Quarter 2009 Financial Results 3Osteotech Reports Third Quarter 2009 Financial Results 4Osteotech Reports Third Quarter 2009 Financial Results 5Osteotech Reports Third Quarter 2009 Financial Results 6Osteotech Reports Third Quarter 2009 Financial Results 7Osteotech Reports Third Quarter 2009 Financial Results 8Its Back to Basics to Save a Life 55079 1Its Back to Basics to Save a Life 55079 2Its Back to Basics to Save a Life 55079 3At last 21 A Remarkable Breakthrough for Parkinson 26apos 3Bs Disease Freezing 3A The GaitAid Virtual Walker 55077 1At last 21 A Remarkable Breakthrough for Parkinson 26apos 3Bs Disease Freezing 3A The GaitAid Virtual Walker 55077 2At last 21 A Remarkable Breakthrough for Parkinson 26apos 3Bs Disease Freezing 3A The GaitAid Virtual Walker 55077 3International Micro Industries 28IMI 29 is ITAR Registered 55075 1International Micro Industries 28IMI 29 is ITAR Registered 55075 2
..., 2007 - According to,The Waismann Method 2006 Opi...ents seeking treatment for opiate dependency have ... OxyContin, Percocet,and Fentanyl were among the d... who reported a dependency said they suffered from...ed addiction,specialist for the Waismann Method., ...
...se,Pharma today announced, that the abstract entit...dy in Pancreatic,Carcinoma, Malignant Melanoma, an...r AP 12009” has been selected for poster,pre...an Society of,Clinical Oncology (ASCO), which will...t - 5th. , In the Phase I/II-trial the antisense d...
Other Medicine Technology:Waismann Method Survey Reveals 65 Percent of Women Seeking Opiate,Dependency Treatment Are Mothers 2Phase I/II-data on Systemic Application of the TGF-beta2-inhibitor,AP 12009 to be Presented 2
(Date:11/7/2009)...mic climate, many Americans are monitoring their p...what that they consider to be absolutely essential...es that it’s very important for overweight a...rove their health, and he is trying to make weight... economy by offering reasonable prices and multipl...
(Date:11/7/2009)...m Greensations fights pain and increases circulati...rmaFeet targets foot pain and soreness with a soot...ut, Goldenseal, Vitamin C and Alpha Lipoic Acid. ,...) November 7, 2009 -- A new foot spray from Greens...the power of hot peppers and caffeine. The main pa...
(Date:11/6/2009)...ia graduate was featured in a local news show abou... special report focused on the growing problem of ...drew shared his near death experience and his beli...n drug abuse. ,, "I woke up, blinked once and the ... top of me giving me CPR. I saw tears streaming do...
(Date:11/6/2009)...h pledge-breaking tax hikes ,, WASHINGTON, Nov. ...or Tax Reform: ,, By formally endorsing the Ho...effectively announced that the central promise of ...gn, Obama made a "firm pledge" not to raise " any...0,000 per year: ,, "I can make a firm pledge. Un...
(Date:11/6/2009)... CNC ) today announced that it will present at tw...w weeks. ,, Next week, at the Credit Suisse 18th A...11-13, 2009, at the Arizona Biltmore Resort and Sp...mber 11th at 4:30 p.m. Mountain Time. Investors an...esentation at: http://w.on24.com/r.htm?e=174781&...
Breaking Medicine News(10 mins):Health News:Dallas Bariatric Surgeon Offers Multiple Options for Patients Considering Weight Loss Surgery in a Rough Economy 2Health News:Dallas Bariatric Surgeon Offers Multiple Options for Patients Considering Weight Loss Surgery in a Rough Economy 3Health News:Hot Peppers and Caffeine Relieve Painful Feet, Toe Fungus and Foot Odor 2Health News:Narconon Drug Rehab of Georgia Graduate Featured on Local News 2Health News:ATR: Obama Lied, His Tax Pledge Died 2Health News:ATR: Obama Lied, His Tax Pledge Died 3Health News:Centene Corporation to Present at Upcoming Healthcare Conferences 2
...ed government document has revealed that at least ...ontroversial NHS// contracts. This situation is en...had said when he asserted that 95 percent of denti...at I think around about 90 to 95 per cent of them ...
...eace has rejected the UN findings that claim an ex...he radioactive fallout of the Chernobyl disaster,/...ys that the number of cancer deaths is closer to 9...accidents in the world and its effects are felt ev...
...University of Michigan study reveals startling res... receive medicines that could protect their heart ...most common in diabetes. Although ACE inhibit...hat they can prevent heart attacks, strokes, kidne...
...ng running battle of Hep C sufferers with the gove...nsation. // The Haemophilia Foundation, who ...er sufferers about $60,000 each in compensation, b...who contracted hepatitis C from donated blood prod...
...: Well known food brands hold many families sway t...s not under the garb of promoting healthy food cul...in of many consumer lobbies that are unable able t...ing a sure shot strategy of appealing to the sensi...
...twenty minutes, a child dies of HIV/AIDS and yet a...hange this pathetic condition //, the United Natio...to launch an ambitious programme to improve the he... to improve the status of children in the economic...
Other Medicine News:Health News:Older Diabetics not taking kidney and heart protective drugs 2Health News:Zimbabwe To Get ?22-Million For Support Of AIDS/HIV Childre 2
HemoPoint H2 Hemoglobin Measurement System
Duet Diabetes Control System
...elf-Sampling: ,Place the ImmunoDip into the urin...recise amount of sample needed for,an accurate t...o completion,in 3 minutes. , Stable, Easy to ...table,for at least eight hours, even if left in ...
... for urinary albumin that allows for early detecti...Waived test has a sensitivity of 18 mg/L and speci...3 minutes with stable viewing results up to 8 hour...kidney disease, the ICON®microALB allows the c...
Medicine Products: